A Pilot Clinical Study to Evaluate the Safety and Efficacy of ZingiVir-H, Herbo-Mineral Drug in Patients with Viral Fever

Abstract

A viral infection develops when an organism's body is attacked by pathogenic viruses, and infectious virus particles attach to and enter susceptible cells. There are a few antiviral medicines available to manage the viral infection. The objective of this pilot clinical study was to demonstrate the preliminary evaluation on the efficacy and safety of ZingiVir-H, a herbomineral Ayurvedic preparation in hospitalized adults diagnosed with viral infection. A total of thirty patients above 18 years of age presenting with fever were enrolled from 3 rd October 2019 to 28 th December 2019 for conducting the pre-test and post-test clinical trial. All the patients were administered with ZingiVir-H tablet (500 mg) orally every 4 th hour along with lukewarm water after light meal. The intervention was continued until the body temperature became normal. Body temperature, Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), C-reactive protein (C-RP), Liver Function Test (LFT), and Renal Function Test (RFT) were recorded after treatment, first follow-up (on 7 th day of discharge) and 2 nd follow-up (on 30 th day from first follow-up date). LFT and RFT were observed before treatment and 2 nd follow-up (on 30 th day from first follow-up date) and the results obtained were analyzed statistically. Repeated measurements with ANOVA recorded a significant decrease in body temperature (within an average of 4.3 days), CBC, ESR, C-RP after the intervention. The LFT and RFT parameters before and after treatments were within the recommended clinical range which established the hepato-renal safety of the ZingiVir-H in the study subjects. This study proved that ZingiVir-H is highly effective and safe in managing viral fever (jwara).